# DREAMM 8 (NCT04484623)

> Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04484623
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Multiple Myeloma
- Interventions: Belantamab mafodotin; Pomalidomide; Dexamethasone; Bortezomib
- Enrollment: 302
- Primary outcome: Progression-Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 88
- X threads: 60
- Podcasts: 25
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dreamm-8-nct04484623

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04484623", "email": "<work email>"}; the inbox owner confirms by the emailed link.